# Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

> **NCT03939533** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 64 (actual)

## Conditions studied

- Primary Immune Deficiency Disorder

## Interventions

- **DRUG:** CUTAQUIG

## Key facts

- **NCT ID:** NCT03939533
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2022-01-03
- **Final completion:** 2022-01-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939533, "Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03939533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*